Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 17, 2006 Stephen D. Simpson	Forest Labs: Is Different Better? Forest isn't your typical pharmaceutical company, and that's both its boon and its bane for investors.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool October 18, 2006 Brian Lawler	Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees.
The Motley Fool May 1, 2006 Stephen D. Simpson	Short-Term Fears Chip Into Forest Investors may be getting a second chance at unconventional Forest Labs. With the stock having pulled back, it's now very close to a tantalizing price.
The Motley Fool October 22, 2009 Robert Steyer	Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.
The Motley Fool January 16, 2008 Brian Orelli	Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again.
The Motley Fool March 31, 2005 Stephen D. Simpson	Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool September 30, 2005 Stephen D. Simpson	Two Pharma Trees Fall The news of a phase 3 trial failure hammers both Forest Labs and Cypress Bioscience. Investors, take note.
The Motley Fool April 19, 2005 Stephen D. Simpson	Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look.
The Motley Fool October 18, 2005 Stephen D. Simpson	Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note.
The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool April 16, 2008 Brian Orelli	Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development.
The Motley Fool February 22, 2011 Brian Orelli	Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share.
The Motley Fool January 19, 2007 Billy Fisher	The Best Drug Stock for 2007: Forest Laboratories Management shows confidence in its company, which has been busy with expansion. Investors, take note.
The Motley Fool February 22, 2011 Ryan McBride	Forest Labs Snaps Up Clinical Data This deal is the latest proof that drug developers with FDA-approved treatments remain hot buyout targets in a pharma industry that is starved for new products to replace brand-name drugs.
The Motley Fool July 19, 2005 Stephen D. Simpson	A Clearing in the Forest? Despite so-so results, the biotech stock's slide may finally be over.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool August 31, 2007 Brian Lawler	4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals.
The Motley Fool March 21, 2007 Brian Lawler	New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary.
The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.
BusinessWeek June 12, 2006 Gene G. Marcial	New Growth At Forest? Forest Laboratories has been a drag among drugmakers.
The Motley Fool February 22, 2006 Stephen D. Simpson	Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note.
The Motley Fool October 16, 2007 Billy Fisher	Forest Labs Isn't Out of the Woods Yet The drugmaker's Q2 profit falls, but the company raises its full-year forecast.
The Motley Fool January 12, 2006 Stephen D. Simpson	Forest Keeps Reloading An agreement with Mylan Labs gives Forest access to a drug that could be launched in 2006. Investors, take note.
The Motley Fool October 30, 2007 Billy Fisher	Is Forest Labs' Nebivolol Ready for Prime Time? Shareholders of the pharmaceutical company have been looking for a way to boost their floundering stock. The FDA's likely approval of hypertension drug Nebivolol may be the answer.
The Motley Fool September 8, 2004 Charly Travers	Will a Clinical Trial Database Help Investors? While this development is certainly good news for patients and physicians, the impact on investors may be minimal, depending upon the type of data that will be released.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
Chemistry World February 25, 2014 Sarah Houlton	Megamerger brings Actavis into R&D race Generic drug giant Actavis is to buy speciality pharmaceutical firm Forest Labs in a deal worth about $25 billion, bringing Actavis into the drug discovery business.
The Motley Fool December 19, 2005 Stephen D. Simpson	Pfizer Wins, a Sector Rejoices The pharmaceutical dodges a bullet and investors find renewed enthusiasm for big-cap pharma.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool May 4, 2006 Stephen D. Simpson	AstraZeneca Snuffs Out Galida Will any of the new dual-PPAR drugs make it to the market? Here's another good reminder for pharmaceutical and biotech investors that you shouldn't count your chickens until the FDA has let them hatch.
The Motley Fool November 28, 2005 Stephen D. Simpson	Merck's Tighter Belt Bet Operational improvements are an expected move for Merck, but won't really improve long-term prospects. But investors must do their own due diligence to make their own calls here.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool February 25, 2004 Brian Gorman	Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry.
The Motley Fool July 18, 2006 Stephen D. Simpson	Universal Forest Taken to the Woodshed Universal Forest may well find itself pushed down below fair value, but stepping up to buy when everyone is still running for the exits is a recipe for near-term pain.
The Motley Fool June 13, 2007 Billy Fisher	The Best Drug Stock for 2007 Revisited With half of the season left, anything can happen and no lead is safe -- especially in the biotech/pharmaceutical industry. For now the leader, Endo Pharmaceutical, is head and shoulders above the rest.
Chemistry World November 27, 2012 Derek Lowe	Full disclosure? I've been meaning to comment on all the recent calls for the drug industry to be more open with its clinical trial data. But it's hard for me to come up with anything more than 'I think it's a good idea!'
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
The Motley Fool June 29, 2011 Isac Simon	Forest Oil's Unique Advantage in the Natural Gas Market Ambitious plans and a sound business model should help this company reap huge returns.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool September 11, 2007 Brian Orelli	Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix...
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
Bio-IT World June 17, 2004 Hope Melville	Is It Safe? Think the safe harbor provision in patent law lets you use patented compounds in all preclinical-phase research? Think again.
The Motley Fool October 21, 2005 Stephen D. Simpson	Is Wyeth Your Happy Pill? The pharma has crawled back from scandal, but growth prospects aren't looking so healthy. Investors should not be in a hurry to pay a premium for these shares today.
The Motley Fool June 1, 2005 Rich Duprey	Able Labs Disabled The generic drug maker recalls its entire inventory over quality concerns. Its stock price cratered 75% the day after the announcement and has since fallen another 30% since then.